
Gouty Arthritis (Gout) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Gouty Arthritis (Gout) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gouty Arthritis (Gout) - Drugs In Development, 2022, provides an overview of the Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline landscape.
Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area and joint redness. Risk factors include obesity, high alcohol intake, injury to a joint, long-standing kidney disease and high intake of foods rich in purines.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gouty Arthritis (Gout) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 19, 9, 2, 22, 4 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.
Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gouty Arthritis (Gout) - Drugs In Development, 2022, provides an overview of the Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline landscape.
Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area and joint redness. Risk factors include obesity, high alcohol intake, injury to a joint, long-standing kidney disease and high intake of foods rich in purines.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gouty Arthritis (Gout) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 19, 9, 2, 22, 4 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.
Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout) (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
133 Pages
- Introduction
- Global Markets Direct Report Coverage
- Gouty Arthritis (Gout) – Overview
- Gouty Arthritis (Gout) – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Gouty Arthritis (Gout) – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Gouty Arthritis (Gout) – Companies Involved in Therapeutics Development
- 3SBio Inc
- Aclaris Therapeutics Inc
- Acquist Theraputics Inc
- Akaal Pharma Pty Ltd
- Allena Pharmaceuticals Inc
- Alnylam Pharmaceuticals Inc
- Aqilion AB
- Arrowhead Pharmaceuticals Inc
- Arthrosi Therapeutics Inc
- C&C Research Laboratories
- Deep Genomics Inc
- DevaCell Inc
- Dianomi Therapeutics Inc
- Dyve Biosciences Inc
- Enzychem Lifesciences Corp
- EryDel SpA
- Fochon Pharmaceutical Ltd
- FortuneRock (China) Ltd
- Fuji Yakuhin Co Ltd
- GeneScience Pharmaceuticals Co Ltd
- Hangzhou Grand Biologic Pharmaceutical Inc
- Hinova Pharmaceuticals Co Ltd
- Horizon Therapeutics Plc
- IcanoMAB GmbH
- InflammatoRx inc
- InventisBio Co Ltd
- Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Jiangsu Kanion Pharmaceutical Co Ltd
- LG Chem Ltd
- Nippon Chemiphar Co Ltd
- Olatec Therapeutics LLC
- PegBio Co Ltd
- Polaris Pharmaceuticals Inc
- Protalix BioTherapeutics Inc
- Rigel Pharmaceuticals Inc
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Yingli Pharmaceutical Co Ltd
- Shanton Pharma Co Ltd
- Stealth Biologics LLC
- Synlogic Inc
- TaiwanJ Pharmaceuticals Co Ltd
- Teijin Pharma Ltd
- Tonghua Dongbao Pharmaceutical Co Ltd
- TWi Biotechnology Inc
- Usynova Pharmaceuticals Ltd
- Wellstat Therapeutics Corp
- West Lake Biomedical Technology (Hangzhou) Co Ltd
- Gouty Arthritis (Gout) – Drug Profiles
- ABP-072 – Drug Profile
- ABP-168 – Drug Profile
- ABP-671 – Drug Profile
- ACQT-1001 – Drug Profile
- ACQT-1127 – Drug Profile
- AKP-11 – Drug Profile
- ALLN-346 – Drug Profile
- ALN-XDH – Drug Profile
- anakinra SR – Drug Profile
- AR-882 – Drug Profile
- ARO-XDH – Drug Profile
- D-0120 – Drug Profile
- dapansutrile – Drug Profile
- diacerein CR – Drug Profile
- dotinurad – Drug Profile
- Ery-Uricase – Drug Profile
- FCN-207 – Drug Profile
- FCN-342 – Drug Profile
- febuxostat – Drug Profile
- Gensci-048 – Drug Profile
- Gout Target 2 – Drug Profile
- HemoShear – Drug Profile
- HP-501 SR – Drug Profile
- HR-091506 – Drug Profile
- HZBio-1 – Drug Profile
- JS-103 – Drug Profile
- LR-19074 – Drug Profile
- Monoclonal Antibody to Inhibit IL1R7 for Musculoskeletal Disorders, Gastrointestinal, Respiratory and Infectious Disease – Drug Profile
- Monoclonal Antibody to Inhibit S100A9 Protein for Autoimmune Disorders, Chronic Inflammation, Neurodegenerative Diseases and Respiratory Infections – Drug Profile
- mosedipimod – Drug Profile
- NC-2500 – Drug Profile
- NC-2700 – Drug Profile
- PB-348 – Drug Profile
- pegadricase – Drug Profile
- PRX-115 – Drug Profile
- R-835 – Drug Profile
- Recombinant Enzyme for Gout and Hyperuricemia – Drug Profile
- Refractory Gout – Drug Profile
- SAP-001 – Drug Profile
- SFR-9350 – Drug Profile
- SHR-4640 – Drug Profile
- Small Molecule to Inhibit NLRP3 for Inflammatory Disease – Drug Profile
- Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia – Drug Profile
- Small Molecules to Inhibit TAK1 for Immunology and Oncology – Drug Profile
- sodium bicarbonate – Drug Profile
- SSGJ-613 – Drug Profile
- SYNB-2081 – Drug Profile
- taininade – Drug Profile
- THDBH-130 – Drug Profile
- THDBH-150 – Drug Profile
- THDBH-151 – Drug Profile
- TJC-0434 – Drug Profile
- TMX-049 – Drug Profile
- topiroxostat – Drug Profile
- UA-007 – Drug Profile
- URAT1 inhibitor 1 – Drug Profile
- URC-102 – Drug Profile
- uriSHELS – Drug Profile
- WT-2107 – Drug Profile
- WTX-221 – Drug Profile
- WTX-223 – Drug Profile
- WXSH-0493 – Drug Profile
- YL-90148 – Drug Profile
- zunsemetinib – Drug Profile
- Gouty Arthritis (Gout) – Dormant Projects
- Gouty Arthritis (Gout) – Discontinued Products
- Gouty Arthritis (Gout) – Product Development Milestones
- Featured News & Press Releases
- Aug 09, 2022: Arthrosi completes AR882 renal impairment study
- Aug 03, 2022: LG Chem enters final stage of clinical development for new gout drug
- Jul 19, 2022: Allena pharmaceuticals announces completion of enrollment of cohorts A and B of ALLN-346 phase 2a study 202 in patients with Gout and stages 2 and 3 chronic kidney disease
- Jun 16, 2022: Atom Bioscience to update clinical development of new drug to treat gout at BIO International Convention, June 13 – 16, 2022, San Diego, CA
- Jun 13, 2022: Selecta Biosciences announces partnership advancements and clinical trial updates
- Jun 02, 2022: Dyve Biosciences announces phase 2 TARGETS study of DYV702 for pain associated with acute gout flares showcased in podium presentation at 2022 EULAR congress
- May 31, 2022: Fortress Biotech announces first patient dosed in phase 1 clinical trial evaluating dotinurad for the treatment of gout in the United States
- Mar 21, 2022: Atom Bioscience announces positive phase 2a results for investigational new drug to treat chronic gout
- Mar 15, 2022: The Phase I clinical trial of Eusen Jianheng's new gout drug UA007 was successfully completed
- Dec 14, 2021: Arthrosi Therapeutics announces patient enrollment in global phase 2b study of AR882
- Dec 02, 2021: Sobi and Selecta Biosciences complete enrolment for gout therapy trial
- Nov 15, 2021: Dyve Biosciences hosting key opinion leader webinar on Gout and DYV702
- Nov 08, 2021: Shanghai Fosun Pharmaceutical (Group) announcement in relation to the approval for Clinical Trial regarding Investigational New Drug of a subsidiary
- Nov 03, 2021: Allena Pharmaceuticals receives Fast Track Designation from FDA for the Development of ALLN-346 for chronic treatment of hyperuricemia in patients with gout and advanced chronic kidney disease
- Nov 02, 2021: Arthrosi presents AR882 posters at ACR 2021
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Gouty Arthritis (Gout), 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Universities/Institutes, 2022
- Table 6: Products under Development by Companies, 2022
- Table 7: Products under Development by Companies, 2022 (Contd..1)
- Table 8: Products under Development by Companies, 2022 (Contd..2)
- Table 9: Products under Development by Companies, 2022 (Contd..3)
- Table 10: Products under Development by Universities/Institutes, 2022
- Table 11: Number of Products by Stage and Target, 2022
- Table 12: Number of Products by Stage and Mechanism of Action, 2022
- Table 13: Number of Products by Stage and Route of Administration, 2022
- Table 14: Number of Products by Stage and Molecule Type, 2022
- Table 15: Gouty Arthritis (Gout) – Pipeline by 3SBio Inc, 2022
- Table 16: Gouty Arthritis (Gout) – Pipeline by Aclaris Therapeutics Inc, 2022
- Table 17: Gouty Arthritis (Gout) – Pipeline by Acquist Theraputics Inc, 2022
- Table 18: Gouty Arthritis (Gout) – Pipeline by Akaal Pharma Pty Ltd, 2022
- Table 19: Gouty Arthritis (Gout) – Pipeline by Allena Pharmaceuticals Inc, 2022
- Table 20: Gouty Arthritis (Gout) – Pipeline by Alnylam Pharmaceuticals Inc, 2022
- Table 21: Gouty Arthritis (Gout) – Pipeline by Aqilion AB, 2022
- Table 22: Gouty Arthritis (Gout) – Pipeline by Arrowhead Pharmaceuticals Inc, 2022
- Table 23: Gouty Arthritis (Gout) – Pipeline by Arthrosi Therapeutics Inc, 2022
- Table 24: Gouty Arthritis (Gout) – Pipeline by C&C Research Laboratories, 2022
- Table 25: Gouty Arthritis (Gout) – Pipeline by Deep Genomics Inc, 2022
- Table 26: Gouty Arthritis (Gout) – Pipeline by DevaCell Inc, 2022
- Table 27: Gouty Arthritis (Gout) – Pipeline by Dianomi Therapeutics Inc, 2022
- Table 28: Gouty Arthritis (Gout) – Pipeline by Dyve Biosciences Inc, 2022
- Table 29: Gouty Arthritis (Gout) – Pipeline by Enzychem Lifesciences Corp, 2022
- Table 30: Gouty Arthritis (Gout) – Pipeline by EryDel SpA, 2022
- Table 31: Gouty Arthritis (Gout) – Pipeline by Fochon Pharmaceutical Ltd, 2022
- Table 32: Gouty Arthritis (Gout) – Pipeline by FortuneRock (China) Ltd, 2022
- Table 33: Gouty Arthritis (Gout) – Pipeline by Fuji Yakuhin Co Ltd, 2022
- Table 34: Gouty Arthritis (Gout) – Pipeline by GeneScience Pharmaceuticals Co Ltd, 2022
- Table 35: Gouty Arthritis (Gout) – Pipeline by Hangzhou Grand Biologic Pharmaceutical Inc, 2022
- Table 36: Gouty Arthritis (Gout) – Pipeline by Hinova Pharmaceuticals Co Ltd, 2022
- Table 37: Gouty Arthritis (Gout) – Pipeline by Horizon Therapeutics Plc, 2022
- Table 38: Gouty Arthritis (Gout) – Pipeline by IcanoMAB GmbH, 2022
- Table 39: Gouty Arthritis (Gout) – Pipeline by InflammatoRx inc, 2022
- Table 40: Gouty Arthritis (Gout) – Pipeline by InventisBio Co Ltd, 2022
- Table 41: Gouty Arthritis (Gout) – Pipeline by Jiangsu Atom Bioscience and Pharmaceutical Co Ltd, 2022
- Table 42: Gouty Arthritis (Gout) – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
- Table 43: Gouty Arthritis (Gout) – Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, 2022
- Table 44: Gouty Arthritis (Gout) – Pipeline by LG Chem Ltd, 2022
- Table 45: Gouty Arthritis (Gout) – Pipeline by Nippon Chemiphar Co Ltd, 2022
- Table 46: Gouty Arthritis (Gout) – Pipeline by Olatec Therapeutics LLC, 2022
- Table 47: Gouty Arthritis (Gout) – Pipeline by PegBio Co Ltd, 2022
- Table 48: Gouty Arthritis (Gout) – Pipeline by Polaris Pharmaceuticals Inc, 2022
- Table 49: Gouty Arthritis (Gout) – Pipeline by Protalix BioTherapeutics Inc, 2022
- Table 50: Gouty Arthritis (Gout) – Pipeline by Rigel Pharmaceuticals Inc, 2022
- Table 51: Gouty Arthritis (Gout) – Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
- Table 52: Gouty Arthritis (Gout) – Pipeline by Shanghai Yingli Pharmaceutical Co Ltd, 2022
- Table 53: Gouty Arthritis (Gout) – Pipeline by Shanton Pharma Co Ltd, 2022
- Table 54: Gouty Arthritis (Gout) – Pipeline by Stealth Biologics LLC, 2022
- Table 55: Gouty Arthritis (Gout) – Pipeline by Synlogic Inc, 2022
- Table 56: Gouty Arthritis (Gout) – Pipeline by TaiwanJ Pharmaceuticals Co Ltd, 2022
- Table 57: Gouty Arthritis (Gout) – Pipeline by Teijin Pharma Ltd, 2022
- Table 58: Gouty Arthritis (Gout) – Pipeline by Tonghua Dongbao Pharmaceutical Co Ltd, 2022
- Table 59: Gouty Arthritis (Gout) – Pipeline by TWi Biotechnology Inc, 2022
- Table 60: Gouty Arthritis (Gout) – Pipeline by Usynova Pharmaceuticals Ltd, 2022
- Table 61: Gouty Arthritis (Gout) – Pipeline by Wellstat Therapeutics Corp, 2022
- Table 62: Gouty Arthritis (Gout) – Pipeline by West Lake Biomedical Technology (Hangzhou) Co Ltd, 2022
- Table 63: Gouty Arthritis (Gout) – Dormant Projects, 2022
- Table 64: Gouty Arthritis (Gout) – Dormant Projects, 2022 (Contd..1)
- Table 65: Gouty Arthritis (Gout) – Dormant Projects, 2022 (Contd..2)
- Table 66: Gouty Arthritis (Gout) – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Gouty Arthritis (Gout), 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Routes of Administration, 2022
- Figure 10: Number of Products by Top 10 Molecule Types, 2022
- Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.